Search Results

Paris and Boston, January 26, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...

Paris and Boston, January 21, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...

4 2025 revenue up 19% on a reported basis (+29% excluding currency effects – CER)  Sales in the United States up 65% (+82% at CER) after three...

Integrating Cellvizio® into TaeWoong’s portfolio of therapeutic devices to create the first fully integrated “imaging-to-therapy” solution for...

NMPA approval obtained following a 3-year certification process  Mauna Kea is now evaluating options to commercialize Cellvizio Gen 3 in China...

70% debt write-off, from €40M to €12M  Remaining debt to be repaid over 10 years, with 90% between the end of 2029 and the end of 2035 ...

Safeguard plan approved by judgment of the Paris Commercial Court on November 12, 2025  Launch of a reserved capital increase in the form of...

New equity financing would provide the Company sufficient financial visibility to execute its strategic plan and achieve profitability  The future...

U.S. sales surge +31% at constant exchange rates, with continued acceleration over the year  Commercial momentum highlighted by a doubling of...

Capital increase of €5m to €8m through a private placement planned for the first half of November via the issuance of shares with attached warrants...

A large majority of creditors and shareholders have voted in favor of the draft safeguard plan  This plan includes a 70% reduction in debt,...

 32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments  Improvement Reflects Strict Expense Control and 17% U.S....